Tianjin Lisheng Pharmaceutical Co Ltd Strategic Asset Allocation Index
Tianjin Lisheng Pharmaceutical Co Ltd strategic asset allocation index. Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Strategic Asset Allocation Index of 21.7% as of September 2023. Strategic assets (PP&E of CN¥1.01 Billion plus long-term investments of CN¥-) total CN¥1.01 Billion, measured against net assets of CN¥4.64 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Tianjin Lisheng Pharmaceutical Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Tianjin Lisheng Pharmaceutical Co Ltd (2007–2021)
Strategic asset allocation index of Tianjin Lisheng Pharmaceutical Co Ltd from 2007 to 2021. This chart shows how Tianjin Lisheng Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 15 annual periods from 2007 to 2021. As of September 2023, the index stands at 21.7%, representing strategic assets of CN¥1.01 Billion against net assets of CN¥4.64 Billion CNY. Check 002393 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Tianjin Lisheng Pharmaceutical Co Ltd Strategic Asset Allocation Index by Year (2007–2021)
Tianjin Lisheng Pharmaceutical Co Ltd strategic asset allocation index by year from 2007 to 2021. The table below presents the year-by-year Strategic Asset Allocation Index for Tianjin Lisheng Pharmaceutical Co Ltd from 2007 to 2021, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Tianjin Lisheng Pharmaceutical Co Ltd market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 25.8% | CN¥1.14 Billion | CN¥1.14 Billion | CN¥- | CN¥4.41 Billion | ▲ +0.5 pp |
| 2020 | 25.3% | CN¥1.09 Billion | CN¥1.09 Billion | CN¥- | CN¥4.30 Billion | ▲ +0.1 pp |
| 2019 | 25.2% | CN¥1.11 Billion | CN¥1.11 Billion | CN¥- | CN¥4.42 Billion | ▼ -18.9 pp |
| 2018 | 44.2% | CN¥1.42 Billion | CN¥1.12 Billion | CN¥294.11 Million | CN¥3.21 Billion | ▲ +7.4 pp |
| 2017 | 36.7% | CN¥1.13 Billion | CN¥1.13 Billion | CN¥- | CN¥3.08 Billion | ▼ -27.9 pp |
| 2016 | 64.6% | CN¥1.95 Billion | CN¥1.64 Billion | CN¥305.91 Million | CN¥3.02 Billion | ▲ +4.5 pp |
| 2015 | 60.2% | CN¥1.79 Billion | CN¥1.55 Billion | CN¥232.18 Million | CN¥2.97 Billion | ▲ +16.7 pp |
| 2014 | 43.5% | CN¥1.27 Billion | CN¥1.27 Billion | CN¥- | CN¥2.91 Billion | ▲ +8.7 pp |
| 2013 | 34.8% | CN¥1.02 Billion | CN¥1.02 Billion | CN¥- | CN¥2.92 Billion | ▲ +10.2 pp |
| 2012 | 24.5% | CN¥683.97 Million | CN¥683.97 Million | CN¥- | CN¥2.79 Billion | ▲ +11.0 pp |
| 2011 | 13.5% | CN¥378.02 Million | CN¥378.02 Million | CN¥- | CN¥2.80 Billion | ▲ +2.4 pp |
| 2010 | 11.1% | CN¥295.02 Million | CN¥295.02 Million | CN¥- | CN¥2.65 Billion | ▼ -45.7 pp |
| 2009 | 56.8% | CN¥267.67 Million | CN¥267.67 Million | CN¥- | CN¥470.87 Million | ▲ +22.4 pp |
| 2008 | 34.4% | CN¥163.37 Million | CN¥163.37 Million | CN¥- | CN¥474.77 Million | ▼ -2.7 pp |
| 2007 | 37.1% | CN¥160.41 Million | CN¥160.41 Million | CN¥- | CN¥432.23 Million | — |